Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Partnership Between Debiopharm and ThinkingNodeLife.ai Aims to Expedite Precision Cancer Drug Advancements

NextEdge Admin

21 Dec 2023

2 min 9 sec

Swiss-based biopharmaceutical company Debiopharm has announced a strategic collaboration with San Diego’s ThinkingNodeLife.ai, utilizing the latter’s artificial intelligence digital cells lab platform to enhance the development of precision cancer drugs. The partnership aims to leverage ThinkingNodeLife.ai’s generative distributed reasoning AI, a distinct approach from conventional machine learning-based systems. This technology focuses on human-like reasoning, integrating data and profound domain knowledge to create models for human cells, known as human digital clones, using gene-expression data.

Within the collaboration, ThinkingNodeLife.ai and Debiopharm will work together on various aspects of cancer drug development. These include exploring new indications for existing cancer drugs, identifying opportunities for combining agents with other therapies, comparing treatment activities, validating drug mechanisms, and pinpointing predictive biomarkers. Debiopharm’s drug development pipeline encompasses several investigational oncology treatments, such as CA IX-targeted radiotherapy Debio 0228, IAP antagonist xevinapant (Debio 1143) for head and neck cancer, and Wee1 kinase inhibitor Debio 0123.

Debiopharm has recently initiated a Phase I/II trial for Debio 0228 in patients with CA IX-expressing solid tumors. The company has also entered collaborations with SunRock Biopharma and Nucleai to advance antibody-drug conjugates for cancer treatment and identify biomarkers for optimal responses to clinical-stage oncology assets, respectively. The integration of ThinkingNodeLife.ai’s advanced AI technology is expected to bolster Debiopharm’s efforts in precision medicine and targeted cancer therapies.